Granulins as Inflammatory Mediators in Alzheimer Disease by Reed, Randi G
The University of Southern Mississippi 
The Aquila Digital Community 
Honors Theses Honors College 
Spring 5-2015 
Granulins as Inflammatory Mediators in Alzheimer Disease 
Randi G. Reed 
University of Southern Mississippi 
Follow this and additional works at: https://aquila.usm.edu/honors_theses 
 Part of the Biochemistry Commons 
Recommended Citation 
Reed, Randi G., "Granulins as Inflammatory Mediators in Alzheimer Disease" (2015). Honors Theses. 293. 
https://aquila.usm.edu/honors_theses/293 
This Honors College Thesis is brought to you for free and open access by the Honors College at The Aquila Digital 
Community. It has been accepted for inclusion in Honors Theses by an authorized administrator of The Aquila 
Digital Community. For more information, please contact Joshua.Cromwell@usm.edu. 
 
 
The University of Southern Mississippi 
 
 
 
 
 
Granulins as Inflammatory Mediators in Alzheimer Disease 
 
 
 
by 
 
 
 
Randi G. Reed 
 
 
 
 
 
A Thesis 
Submitted to the Honors College of 
The University of Southern Mississippi 
in Partial Fulfillment 
of the Requirements for the Degree of 
Bachelor of Science 
in the Department of Chemistry and Biochemistry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
May 2015 
ii 
 
  
iii 
 
Approved by 
 
 
 
 
 
____________________________________ 
Vijay Rangachari, Ph.D., Thesis Adviser 
Department of Chemistry and Biochemistry 
 
 
 
 
 
 
 
 
 
____________________________________ 
Sabine Heinhorst, Ph.D., Chair 
Department of Chemistry and Biochemistry 
 
 
 
 
 
 
 
 
 
____________________________________ 
Ellen Weinauer, Ph.D., Dean 
Honors College 
  
iv 
 
Abstract 
Alzheimer disease (AD) is a neurodegenerative disorder characterized by severe 
memory deficit and cognitive decline among the elderly. This degeneration is caused by 
the aggregation and deposition of a protein called amyloid-β (Aβ) in the brain.  Aggregation 
of Aβ causes neuroinflammation in addition to other toxic events. However, it is unclear 
whether inflammation from an external source, such as from a traumatic brain injury (TBI), 
could trigger Aβ aggregation. In this context, several pro-inflammatory mediators such as 
cytokines and chemokines have been suspects. It is now hypothesized that a group of 
proteins called granulins (Grns) are unique inflammatory mediators that can interact and 
modulate Aβ aggregation. Grns are a family of seven (A-G) small, cysteine-rich proteins 
that are proteolytically cleaved from a precursor protein called progranulin (PGrn) during 
neuroinflammation. Grns have been implicated in both AD and frontotemporal lobar 
degeneration (FTLD). Among the seven Grns, my work is primarily focused on GrnE. 
GrnE was recombinantly expressed in E. coli and purified using affinity chromatography. 
The structural characteristics were studied using several biochemical and biophysical 
techniques, such as sodium dodecyl sulfate (SDS) and native gel electrophoresis, circular 
dichroism (CD), and fluorescence spectroscopy. The collective data suggest that GrnE is 
an intrinsically disordered protein (IDP) and is able to dimerize at high concentrations. This 
is a novel finding because GrnE is not expected to be disordered due to its high degree of 
intramolecular disulfide bonds. Additionally, Grns C and F have been successfully 
expressed in E. coli.   
Keywords: Alzheimer disease, granulin, progranulin, neuroinflammation 
v 
 
Acknowledgements 
I would first like to express my gratitude to my adviser Dr. Vijay Rangachari for 
not only his help and guidance with this project, but also for his invaluable life lessons. 
Secondly, I give special acknowledgment to my graduate mentor, Gaurav Ghag, for his 
patience in guiding me through this research and for his endless encouragement. Lastly, I 
thank all of the people that made my time working on this project a fun and memorable 
one: Dexter Dean, Christopher Mullins, Tisha Sellers, and Ramya Murali.  
The USM Center for Undergraduate Research (Eagle SPUR) and Mississippi 
INBRE are gratefully acknowledged for their generous funding of this project.  
  
vi 
 
Table of Contents 
List of Tables .................................................................................................................... vii 
List of Figures .................................................................................................................. viii 
Chapter 1: Introduction ........................................................................................................1 
Chapter 2: Background ........................................................................................................3 
2.1 Alzheimer Disease and Amyloid-β ....................................................................3 
2.2 Granulins and Neuroinflammation ....................................................................4  
2.3 Research Objectives ...........................................................................................6 
Chapter 3: Methodology ......................................................................................................7 
3.1 Expression ..........................................................................................................7 
3.2 Purification .........................................................................................................8 
3.3 Biophysical Characterization of GrnE .............................................................10 
Chapter 4: Results and Discussion .....................................................................................14 
4.1 Recombinant Expression of GrnE ...................................................................14 
4.2 Biophysical Characterization of GrE and GrnB ..............................................16 
4.3 Recombinant Expression of Other Grns ..........................................................19 
Chapter 5: Conclusions ......................................................................................................20 
5.1 Grn Conclusions...............................................................................................20 
5.2 Future Directions .............................................................................................21 
References ..........................................................................................................................22 
  
vii 
 
List of Tables 
Table 1: Summary of purification buffers ...........................................................................9 
Table 2: Summary of Ellman’s assay reactions .................................................................11 
  
viii 
 
List of Figures 
Figure 1: The domain structure of PGrn ..............................................................................4 
Figure 2: Cloning region of pET32b:GrnE ..........................................................................7 
Figure 3: Restriction digestion ...........................................................................................14 
Figure 4: Small scale expression and Ni-NTA purification...............................................15 
Figure 5: HPLC profiles.....................................................................................................15 
Figure 6: SDS-PAGE .........................................................................................................16 
Figure 7: Native PAGE ......................................................................................................16 
Figure 8: Circular dichroism ..............................................................................................17 
Figure 9: ANS binding assays............................................................................................18 
Figure 10: GrnB intrinsic tryptophan fluorescence assay ..................................................19 
Figure 11: Small scale expression of GrnF ........................................................................19 
 
 
1 
 
Chapter 1- Introduction 
Alzheimer disease (AD) is a debilitating neurodegenerative disorder that leads to 
dementia and impaired cognitive function and memory. The acute neuronal loss that occurs 
in AD has been associated with the aggregation of a protein called amyloid-β (Aβ), which 
leads to the formation of toxic oligomers and fibrils. In addition to triggering neurotoxicity 
via different cellular mechanisms, the aggregates are also known to induce severe 
inflammation. Although little ambiguity remains about this mechanism, the reverse effect 
of inflammatory reactions in triggering Aβ aggregation and concomitant cognitive 
dysfunction is unclear.  There is increasing clinical evidence to support inflammation-
induced Aβ aggregation, which comes from the documented cases of traumatic brain injury 
(TBI). These responses are known to result in AD-type dementia in patients. It is known 
that about 50% of cases of AD related to frontotemporal dementia (FTD) are familial, or, 
in other words, genetic. Therefore, the remaining 50% of cases are the sporadic form of 
AD, which is affected by the environmental conditions of Aβ.  Despite clinical and 
pathological evidence implicating inflammation-triggered neurodegeneration, the 
underlying molecular events involved in such mechanisms largely remain unclear.   
In this regard, pro-inflammatory molecules involved in the cascade, such as 
chemokines and cytokines, have been the usual suspects, but a unique biomarker for 
inflammation-induced AD has not yet been identified.  In this context, progranulin (PGrn), 
a protein which is known to play a role in the processes of wound healing and injury repair, 
is a key suspect mainly due to its involvement in neurodegenerative pathology, such as that 
seen in FTD. Among patients with AD, PGrn is upregulated in neuronal microglia 
surrounding Aβ plaques. During an inflammatory event, microglia are activated in the 
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brain, which in turn release proteases, such as neutrophil elastase, that cleave PGrn into 
seven smaller pro-inflammatory proteins called granulins (Grns A-G).  Based on the known 
PGrn/Grn involvement in dementia and the pro-inflammatory nature of Grns, it is 
hypothesized that Grns may have unique interactions with Aβ.  Although Grns are 
implicated in neurodegenerative diseases, their precise molecular interactions with Aβ 
have not yet been studied in the context of inflammation-triggered aggregation.  In this 
context, GrnA and GrnB are being characterized in our laboratory. Our results indicate 
interactions with Aβ peptides (unpublished data). For this project, my research focus is on 
expressing Grns C, E, and F and specifically, characterizing GrnE.  This research plans to 
accomplish the following:  
1. Express Grns C, E, and F in E. coli and purify.  
2. Characterize GrnE and compare those results to GrnB.   
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Chapter 2- Background 
2.1 Alzheimer Disease and Amyloid-β 
 Alzheimer disease is characterized by memory impairment, loss of cognitive 
function, and altered behavior that can include paranoia and a loss of social appropriateness 
(1).  Many studies via animal models have produced biochemical data that suggest AD is 
caused by the aggregation of Aβ, which forms toxic oligomers and fibrils (2).  In familial 
forms of AD, it has been observed that mutations in amyloid precursor proteins (APP) or 
presenilins lead to the overexpression of Aβ (3, 4).  However, the augmentation of Aβ 
aggregation by an environmental cause, such as a physical head injury, a viral infection, or 
severe stress, causing sporadic AD is not well-understood. Growing amounts of clinical 
evidence support that TBIs like these are the cause of inflammatory reactions that can 
trigger Aβ aggregation and later sporadic AD (5).   
 During inflammation, proteins such as α1-antichymotrypsin, interleukin-6 (IL-6), 
and C-reactive protein are released in the brain  Studies show that plasma samples with 
increased levels of these inflammatory proteins occur before the onset of clinical AD (6). 
Furthermore, for the past 15 years, studies have shown that prolonged use of non-steroidal 
anti-inflammatory drugs (NSAIDS) have been fairly successful in preventing 
neurodegenerative diseases such as AD (7). This evidence supports the thought that 
neuroinflammation may be a cause of AD rather than only a consequence.  
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2.2 Granulins and Neuroinflammation 
 As mentioned earlier, Grns are generated from their precursor protein, PGrn. PGrn 
is found in high levels, along with its messenger RNA, in peripheral blood in patients with 
AD (8). Human PGrn is a 68.5 kDa protein that is rich in cysteine and is made up of seven 
and a half smaller Grn domains (Grns A-G and a half Grn P) (Figure 1) (9).  These Grns 
are generated when proteases, such as neutrophil elastase, are released in large quantities 
by microglia during inflammation and act on PGrn by cleaving it at specific linker regions 
(10). The cleavage sites have been mapped, although the specific proteolytic enzyme(s) 
that acts on the sites in Grns F, B, and A is unknown. Each Grn is ~6 kDa and contains a 
motif of 12 cysteine residues consisting of four central pairs flanked by a single pair on 
each terminus.  
 
 
 
 
 
 
 
  
 
Figure 1- The domain structure of PGrn. The boxed letters denote Grn domains arranged from the N-
terminus to the C-terminus. The NMR structure of GrnA is seen above. Scissors denote the elastase 
cleavage sites. Asterisks denote linker regions where proteolytic cleavage occurs, but the protease has 
not yet been identified. On the bottom is the amino acid sequence of GrnA (9).  
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The homeostasis between PGrns and Grns is maintained by serine leukocyte 
protease inhibitor (SLPI), which prevents elastase from cleaving PGrn (11).  Grns stimulate 
epithelial cells to secrete interleukin-8, which initiates an immune response. However, 
PGrns have no such effect, but rather inhibit the spreading, degranulation, and respiratory 
burst of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) (10). 
These contrasting effects, the anti-inflammatory and pro-inflammatory of PGrns and Grns, 
respectively, could be responsible for the involvement of microglia in either a deficient or 
an overactive response to injury and the later development of AD or other types of dementia 
(12, 13).  
PGrns are known to play a role in many categories of biological function, including 
growth-factor-like activities, modulation of immune responses, and neuronal effects (9). 
Notably, PGrn is heavily involved in wound repair, predominantly in epithelial and 
hematopoietic cells (14). As discussed earlier, PGrns/Grns also play an important role in 
neurodegeneration. The PGrn gene is located on chromosome 17 in humans, and it has 
been shown that mutations in this gene can result in a familial form of dementia known as 
FTD and specifically frontotemporal lobar degeneration (FTLD) (13).  
Since PGrn expression is upregulated in microglial cells that are localized with Aβ 
(12), this overexpression could play a critical role in the response to brain injury, 
neuroinflammation, and neurodegeneration. Depositions of Aβ plaques trigger 
inflammatory cascades, which activate the microglia to secrete various pro-inflammatory 
mediators that may affect Aβ aggregation. Acute inflammation triggered by other factors 
like a TBI activates the microglia that secrete elastases and other proteases, which in turn 
cleave PGrn to produce pro-inflammatory Grns (11). These Grns could then interact with 
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extracellular Aβ by either exacerbating or mitigating its aggregation and modulating the 
onset of AD, depending on the extent of the initial inflammatory response.   
2.3 Research Objectives  
The purpose of this research is to express Grns C, E, and F and to specifically 
characterize GrnE. The objectives to accomplish this goal are:   
1) Expression of Grns C, E, and F in E. coli cells.  
2) Purification using affinity chromatography and high performance liquid 
chromatography (HPLC).  
3) Characterization of GrnE using gel electrophoresis and biophysical tools such 
as fluorescence and circular dichroism spectroscopy. 
4) Comparison of the results obtained for GrnE to data of GrnB.  
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Chapter 3- Methodology 
3.1 Expression  
The following describes specifically the expression of GrnE. The other Grns are 
expressed using these same methods.  
The gene for GrnE and the other Grns were synthesized commercially (GENEWIZ 
Inc, NJ). The GrnE gene was inserted into a pET32b plasmid that was readily available in 
the lab. The cloning region (Figure 2) contains a thioredoxin tag which is known to 
promote disulfide bonds, a hexa-histidine (His6) tag for Ni2+ affinity purification, and a 
thrombin cleavage site upstream from the GrnE gene to separate GrnE from the rest of the 
fusion protein after expression. The plasmid also contains an ampicillin resistance gene to 
selectively grow the cells containing the plasmid.   
 
 
 
 
 To confirm the presence of the correct gene, the plasmid was extracted from the 
cells using a Zyppy™ Plasmid Miniprep Kit, and then was used in a restriction digestion. 
The enzymes XhoI and XbaI were used with 10x BSA, 10x NEB4 Buffer, sterile water, 
and ~300 ng/μL of plasmid DNA, with a total volume of 10 μL. Each sample was run on a 
0.8% agarose gel and stained with ethidium bromide. Two distinct bands at 650 base pairs 
and 4500 base pairs would confirm plasmid insertion.  
 
Figure 2: Cloning region of pET32b:GrnE. This vector contains a thioredoxin site, a hexa-histidine 
tag, a thrombin cleavage site, and the GrnE expressing gene. These sites are important for disulfide 
pairing, purification, and expression. (Genes are not drawn to scale.) 
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 Upon confirmation, small scale expression was carried out. Cultures of 6 mL were 
grown in LB broth and cell growth was measured by recording the optical density (OD) at 
600 nm on a Cary 50 UV-Vis spectrophotometer (Agilent Technologies). When the OD 
reached 0.5-0.7 AU (absorbance units), half of each culture was induced with isopropyl β-
D-1-thiogalactopyranoside (IPTG) at 0.9-1.0 mM and allowed to grow for four additional 
hours, prompting overexpression of the fusion protein, GrnE-trxA. The cells were then 
spun down and the pellets washed by resuspending in 750 μL sterile water. Both induced 
and un-induced samples were electrophoresed on a sodium dodecyl sulfate polyacrylamide 
gel (SDS-PAGE). An intense band at ~20 kDa observed in the induced samples would 
confirm expression of GrnE-trxA. For large scale expression, 1-2 L of sterile LB broth 
were inoculated with overnight cultures of cells and grown until the cell density was 
between 0.5-0.7 AU. The cells were then induced using 0.9-1.0 mM IPTG for four hours, 
after which they were harvested by centrifuging at 14,000xg for ten minutes and were either 
used immediately or stored at -20 °C until use.  
3.2 Purification 
The purification of GrnE was first performed similarly to the protocols standardized 
for Grns A and B in our laboratory. The cells were resuspended in column equilibration 
buffer (Table 1) and had phenylmethylsulfonyl fluoride (PMSF) added to inhibit proteases. 
The cells were lysed by sonication (6 cycles of 20 seconds with 1 minute intervals on ice) 
before subjecting to centrifugation at 9,500xg for 15 minutes. The supernatant was then 
loaded on to the Ni2+-NTA affinity column that was kept pre-equilibrated with loading 
buffer. The hexa-histidine tag on the fusion protein bound to the nickel beads (HisPurTM 
Ni-NTA resin, Thermo Scientific), allowing the other components of the supernatant to 
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flow through. Urea was added to the washes in decreasing amounts to enable unfolding of 
the protein and facilitate the binding of the His-tag to Ni2+. The washes were also made 
with buffer containing steadily increasing concentrations of imidazole. Imidazole is a 
compound that has a higher affinity for nickel than histidine has and hence, the imidazole 
washes removed non-specific binding proteins before the wash with the highest imidazole 
concentration (500 mM, Table 1) was finally run through, which allowed the purified 
protein to elute. 
Wash Imidazole (mM) Urea (M) Total volume (mL) 
Column Equilibration 10 6 100 
Wash 1 80 4 100 
Wash 2 100 2 100 
Elution buffer 500 0 20 
 
Table 1: Purification buffers with their imidazole and urea concentrations. Each also contained 50 mM Tris-HCl and 300 
mM NaCl and had their pH adjusted to 6.5.  
 
The column was finally stripped with 15 mL of a 300 mM NaCl, 20 mM Tris-HCl, 100 
mM EDTA solution. This strips anything that might have remained bound to the beads and 
readies the column for the next purification. 
The eluted fraction containing GrnE-trxA was confirmed by polyacrylamide gel 
electrophoresis (PAGE). The fraction was then reduced with 5 mM tris(2-
carboxyethyl)phosphine-HCl (TCEP-HCl), followed by a 10x dilution in a 50 mM Tris-
HCl, 300 mM NaCl pH 6.5 buffer in an effort to facilitate only intramolecular disulfide 
bond formation. Dialysis was then performed using 10kDa MWCO (molecular weight cut 
off) Spectra/Por® dialysis membranes (Spectrum Labs) in 5 L of 0.2 mM Tris-HCl, 0.5 
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mM NaCl buffer. Buffer was replaced four times after every two hours to remove any 
remaining imidazole, TCEP-HCl, or salts. After drying in a vacufuge and resuspending the 
fusion protein in 2 mL of sterile water, thrombin cleavage was initiated by incubating the 
protein with thrombin enzyme (1 U thrombin/200 µg protein) overnight in order to cleave 
GrnE from the thioredoxin fusion. Finally, cleaved GrnE was purified using a 
LiChroCART C-18 reverse phase high performance liquid chromatography (HPLC) 
column (Merck, Germany) on an AKTA FPLC system (GE Healthcare, Buckinghamshire). 
GrnE was fractionated with a gradient of 30-90% acetonitrile containing 0.1% 
trifluoroacetic acid. The fractionation resulted in the protein separating from thioredoxin 
in an undigested form along with isoforms of GrnE, eluting in fractions 8 and 9. The 
fractions were dried in a vacufuge and later resuspended in 100 μL of 20 mM Tris, 0.010% 
NaN3.  
3.3 Biophysical Characterization of GrnE  
3.3.1 SDS-PAGE 
 Fractions from HPLC were run on an 8-16% SDS-PAGE gel. Each fraction had 
reduced, non-reduced, and non-reduced/non-boiled samples. This was performed to 
discern any information about GrnE’s oligomeric state.  
 3.3.2 Native PAGE 
 GrnE samples of concentrations 25 and 50 µM were run on a native gel. Native gels 
contain no SDS, allowing proteins to run at their native conformation. Running buffer 
(10X) consisted of 25 mM Tris base and 192 mM glycine. The pH was adjusted to 11.3. 
Since the predicted pI of GrnE is 8.05, the buffer must have a higher pH so that the protein 
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has a net negative charge and migrates to the positive electrode during electrophoresis. A 
20 µM Aβ42 was run alongside GrnE as a control.  
 3.3.3 Ellman’s Assay 
Ellman’s assay was performed on GrnE fractions to determine the concentration of 
free cysteine residues. This was accomplished by adding Ellman’s reagent, 5-5’-dithiobis-
2-nitrobenzoic acid (DTNB), to a protein where it reacts with free thiols, which cleave the 
disulfide bond in DTNB. The result is TNB-, which ionizes to TNB2- in water. This product 
has a yellow color which was quantified using UV spectroscopy. Different concentrations 
of GrnE fractions were used in these reactions. The volumes used are described in Table 2.  
GrnE 6.25 µL protein 1.25 µL DTNB 62.5 µL Tris, pH 6.5 
Blank 6.25 µL water 1.25 µL DTNB 62.5 µL Tris, pH 6.5 
 
Table 2: Reactions made for Ellman’s assay.  
 
The reactions were incubated at room temperature for 15 minutes before the 
absorbance was measured at 412 nm. The extinction coefficient of the reagent, 14150 M-
1cm-1, was then used to measure the amount of free cysteine residues present.  
3.3.4 Circular Dichroism 
Circular dichroism (CD) spectroscopy is a technique in which the CD (difference 
of absorption between left-handed and right-handed circularly polarized light) is measured 
over a range of wavelengths. The resulting spectrum provides information about a protein’s 
secondary structure based on its minimum absorbance wavelength. CD spectra of fractions 
at concentrations of 2 µM and 20 µM were obtained using a Jasco J-815 spectrometer 
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(Jasco Inc, Easton, MD). The samples were monitored in a continuous scan mode from 260 
to 198 nm with a scanning speed of 50 nm/min with a data integration time of 8 s, 1 nm 
bandwidth, and the data pitch of 0.1 nm. Each data set was an average of three scans.  
3.3.5 ANS Binding Assay  
Anilinonaphthalene-8-sulfonate (ANS) is a compound that non-specifically binds 
to hydrophobic amino acid residues. When bound, it excites at 380 nm which can be 
measured using a fluorometer, here a Cary Eclipse spectrometer (Agilent Inc). Scans were 
obtained by exciting the samples at 380 nm and scanning from 410-600 nm with both 
excitation and emission slits set at 10 nm. Every data set was an average of three scans. An 
ANS assay was performed on decreasing amounts of GrnE by titrating the highest 
concentration with 500 mM ANS and 20 mM Tris, pH 6.5 (keeping these concentrations 
constant). A negative control was also performed under the same conditions using bovine 
serum albumin (BSA), a protein that only slightly dimerizes (15).  
3.3.6 Intrinsic Tryptophan Assay  
 Each granulin has a tryptophan in its amino acid sequence which can be used as a 
probe to characterize the protein by fluorescence spectroscopy. Tryptophan fluorescence 
is sensitive to its environment. As tryptophan gets buried within the hydrophobic pocket 
of a protein, its fluorescence increases. This change can be monitored as a function of 
protein concentration, indicating a conformational change. The change in fluorescence 
intensity was monitored over decreasing amounts of Grn by titrating the protein with 20 
mM Tris-HCl buffer, pH 6.5. This was performed on the Cary Eclipse spectrometer with 
emission spectral scans between 320-400 nm arising from the intrinsic tryptophan 
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fluorescence being measured by exciting the samples at 280 nm. The excitation and 
emission slits were set at 10 or 20 nm. As in the CD spectroscopy and ANS assay, each 
data set was the average of three scans.  
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Chapter 4- Results and Discussion 
4.1 Recombinant Expression of GrnE 
After transforming competent E. coli cells with the pET32b:GrnE plasmid, 
confirmation of the presence of the gene in the extracted plasmids was initiated by a 
digestion using restriction enzymes. Digestion by the restriction enzymes XhoI and XbaI 
should result in two bands: one at ~650 base pair and one at ~4500 base pair. These bands 
were indeed observed when 
the isolated plasmids were 
digested with the 
endonucleases (Figure 3).  
Once the presence of 
the insert was confirmed in the 
plasmid, the encoded protein 
was expressed on a small 
scale.  Both induced and un-induced culture samples were run on a 4-20% SDS-PAGE gel 
(Figure 4A). As seen in the figure, a band just under 20 kDa is more prominent in the 
induced than in the un-induced samples. This corresponds to expression of GrnE.   
The positively expressing colonies were then used for expression on a large scale 
as described in the methods. Aliquots of each step of recombinant protein affinity 
purification (pellet, supernatant, flow-through, wash 1, wash 2, elution, and strip) were 
electrophoresed on a 4-20% SDS-PAGE gel (Figure 4B). An intense band at ~20 kDa in 
the elution confirmed the purification of the GrnE-trxA fusion protein.   
 
Figure 3: Restriction digestion. 8% polyacrylamide gel 
displaying plasmid DNA isolated from transformed E. coli 
following restriction digestion with XhoI and XbaI. Two bands 
result at 4500 base pair and 650 base pair.  
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The eluted protein was then reduced, diluted, and dialyzed before being digested 
with thrombin overnight to later be purified by HPLC. The profiles of both GrnE and 
GrnB can be seen in Figure 5.  
 
 
 
 
 
 
 
 
  
Figure 5: HPLC profiles. GrnE elutes at fractions 8 and 9 while 
GrnB elutes in fractions 9 and 10, an indication that the 
biophysical characteristics of these two proteins may be different.  
 
 
Figure 4: A- Small scale expression of pET32b:GrnE-containing E. coli cells on 4-20% SDS-PAGE 
gel. Induced (I) colonies show dark band under 20 kDa, un-induced (U) colonies do not. B- Ni-NTA 
Purification. 4-20% SDS-PAGE gel of Ni2+-NTA purification. Lane 1 is the pellet after centrifugation, 
2 is the resulting supernatant, 3 is the initial flow-through of the column, and 4 and 5 are washes 1 and 
2, respectively. Lane 6 is the elution in which you can see the GrnE-trxA band. Lane 7 is the strip.  
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4.2 Biophysical Characterization of GrnE and GrnB 
 4.2.1 SDS-PAGE 
Reduced, non-reduced, and non-
reduced/non-boiled samples of GrnE were 
run on an 8-16% SDS-PAGE gel as seen 
in Figure 6A. The bands correspond to 
~12 kDa, the expected weight of a dimer. 
However, in lane 1, the reduced band also 
falls in this dimer range. Considering that 
all the disulfide bonds should have been 
reduced in the denaturing gel, the protein 
is expected to run as a monomer corresponding to ~6 kDa. This is the first indication that 
GrnE may have a potential to dimerize.  
4.2.2 Native PAGE 
In order to 
unambiguously characterize 
the dimer formation, GrnE was 
then run on a native PAGE gel 
at pH 11.3 (Figure 7A). 
Concentrations of 25 and 50 
µM GrnE were run alongside a 
control of 25 µM Aβ42. The Aβ resulted in three bands, a 4.5 kDa monomer, a 9 kDa 
     
Figure 7: Native PAGE. A- Lanes 1 and 2 are 25 μM and 50 
μM GrnE, respectively. Lane 3 is 25 μM Aβ42, resulting in a 
monomer (M, 4.5 kDa), dimer (D, 9 kDa), and a trimer (T, 13.5 
kDa). B- Lane 1 is 100 μM GrnB. Lane 2 is 25 μM Aβ42, also 
resulting in a monomer (M), dimer (D), and a trimer (T).  
 
Figure 6: SDS-PAGE (8-16%) gels of Grn 
fractions after HPLC purification. A- GrnE lanes 1-
3 are reduced, non-reduced, and non-reduced/non-
boiled samples, respectively, which fall at ~12 kDa. 
B- Lanes GrnB 1-3 are in the same order, falling at 
~6 kDa.  
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dimer, and a 13.5 kDa trimer. The GrnE bands migrated significantly less than all three of 
the Aβ bands, suggesting that GrnE forms oligomers. On the other hand, GrnB (100 μM) 
shows a dimeric band approximately corresponding to 11 kDa (Figure 7B) when compared 
with Aβ, confirming that GrnB indeed forms a dimer. 
 4.2.3 Ellman’s Assay 
 By calculating the concentration of cysteine residues in the sample of GrnE and 
comparing it to the absorbance obtained at 412 nm, the percentage of free cysteine residues 
was found to be ~7%. This low percentage suggests that the majority of the protein is in its 
physiological form.  
 4.2.4 Circular Dichroism 
Two concentrations of GrnE, 2 and 20 µM, underwent CD spectroscopy. The result 
was a random coil with spectra minimum at ~200 nm (Figure 8A). This lack in structure 
could explain the conundrum seen earlier in the reduced lane of the SDS-PAGE gel (Figure 
6A). Intrinsically disordered proteins (IDPs) are known to run slightly higher than their true 
 
Figure 8: Circular dichroism. A- 2 µM and 20 µM GrnE. Both result in minima of ~202, suggesting 
a randomly coiled, disordered secondary structure. B- GrnB from 10 μM up to 500 μM. Structure is 
gained as concentration increases.  
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molecular weights on gels (16) and have little to no structure at low concentrations (16, 
17). The CD spectra of GrnE at low concentrations show similar results to those of GrnB 
(Figure 8B), which has been characterized as an IDP (unpublished data). GrnB, at low 
concentrations, is unstructured, but gains structure as concentration increases.   
4.2.5 ANS Binding Assay  
ANS binding assays were performed on GrnE along with a BSA negative control. 
As the concentration of GrnE increased, ANS fluorescence also increased (Figure 9A). 
This change was the opposite of the ANS data for GrnB (Figure 9B), which can be fitted 
to a monomer-dimer model. In contrast, although GrnE showed significant concentration-
dependent changes, the data could not be fitted to a dimer model perhaps due to the 
formation of oligomers as indicated by the native gel data (Figure 7A).  
  
 
Figure 9: ANS binding assays. A- GrnE shows an almost sigmoidal curve; as concentration increases, 
fluorescence increases, suggesting a conformational change in the protein. B- GrnB shows an opposite 
shape; however, the plot fits to a monomer-dimer model. As concentration increases, fluorescence 
decreases. In both images, BSA shows minor increase in fluorescence as concentration increases due to 
its slight tendency to dimerize.  
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4.2.6 Intrinsic Tryptophan Assay  
An intrinsic tryptophan assay 
was performed on GrnB, but not on 
GrnE because not enough of the protein 
could be purified to perform enough 
trials. In Figure 10, it can be seen that as 
concentration of GrnB increases, 
fluorescence increases. This suggests a 
conformational change as the tryptophan 
residue becomes more buried in the hydrophobic pocket of the protein. This data is in 
agreement with the ANS binding assay data. 
4.3 Recombinant Expression of Other Grns 
 Cloned genes for Grns C and were 
transformed via the same methods 
described, and GrnF has been expressed on 
a small scale. Figure 11 confirms that GrnF 
is overexpressing; future plans include 
scaling up its expression to obtain pure 
protein for biophysical and biochemical 
characterization.   
  
 
Figure 11: Small scale expression of GrnF. 
The induced lane (I) shows a dark band under 20 
kDa, whereas the un-induced lane (U) does not.  
 
  
Figure 10: Intrinsic tryptophan assay.  As GrnB 
increases in concentration, fluorescence increases.  
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Chapter 5- Conclusions 
5.1 Grn Conclusions 
 In the first part of this project, expression and purification of GrnE, was optimized. 
This took many trials and significant modification of the protocol to accomplish. After 
expression, GrnE was purified using the protocol already generated for GrnB. However, it 
was quickly discovered that the two proteins could not be purified using the same method, 
perhaps due to the differences in their structure. Therefore, the protocol underwent several 
modifications (over 7 rounds of purification) before GrnE was finally purified in a large 
enough amount to move forward. GrnE was not found in the elution until the imidazole 
concentration was increased over twice the amount described in the original GrnB protocol. 
 Based on the CD data obtained (Figure 8), it was clear that GrnE is an IDP because 
this class of proteins lacks three-dimensional conformation and secondary structure. The 
SDS-PAGE gel findings also support this notion because in the reduced lane from Figure 
6A, the protein was shown at a molecular weight higher than what was expected, which is 
another characteristic of IDPs. GrnE and GrnB seem to share this characteristic of disorder 
while having only 40% sequence similarity. What is surprising, however, is the difference 
in ANS binding data (Figure 9). The granulins both showed a transition, but an opposite 
transition. This indicates that while they both undergo concentration-dependent changes, 
those changes may be conformationally different.  
 In line with the second part of this project, the genes for Grns C and F have been 
transformed successfully and expression of GrnF has been achieved. It is important to note 
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that all of these Grns (C-G) have different yields and levels at which they express, most 
likely due to their somewhat low sequence similarity.   
 The inference that GrnB and GrnE are both IDPs is novel as they have a high degree 
of disulfide bonds. In fact, to the best of our knowledge, Grns are the only family of IDPs 
containing six disulfide bonds. 
5.2 Future Directions  
 GrnE needs to undergo more probing for its dimerization characteristics by more 
ANS binding assays and intrinsic tryptophan fluorescence assays. When characterized, 
GrnE must then have its effects with Aβ characterized by an array of fluorescence and 
turbidity assays.  
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